Michael Moran's Insider Trades & SAST Disclosures
Michael Moran's most recent trade in Chewy Inc - Ordinary Shares - Class A was a trade of 189 Class A Common Stock done at an average price of $32.6 . Disclosure was reported to the exchange on Aug. 2, 2023.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael Moran.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Chewy Inc - Ordinary Share... | Michael Morant | General Counsel | Sale of securities on an exchange or to another person at price $ 32.62 per share. | 02 Aug 2023 | 189 | 41,282 (0%) | 0% | 32.6 | 6,165 | Class A Common Stock |
| Chewy Inc - Ordinary Share... | Michael Morant | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jul 2023 | 95,604 | 95,604 (0%) | 0% | 0 | Class A Common Stock | |
| Chewy Inc - Ordinary Share... | Michael Morant | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2023 | 10,885 | 10,885 (0%) | 0% | 0 | Class A Common Stock | |
| Eagle Pharmaceuticals Inc | Michael Moran | EVP, Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 10,400 | 32,115 (0%) | 0% | 0 | Common Stock | |
| Eagle Pharmaceuticals Inc | Michael Moran | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.03 per share. | 02 Feb 2022 | 742 | 21,715 (0%) | 0% | 45.0 | 33,412 | Common Stock |
| Eagle Pharmaceuticals Inc | Michael Moran | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.94 per share. | 31 Jan 2022 | 210 | 22,457 (0%) | 0% | 45.9 | 9,647 | Common Stock |
| Eagle Pharmaceuticals Inc | Michael Moran | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.63 per share. | 07 Jan 2022 | 90 | 22,667 (0%) | 0% | 50.6 | 4,557 | Common Stock |
| Eagle Pharmaceuticals Inc | Michael Moran | EVP, Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 50.69 per share. | 05 Jan 2022 | 1,511 | 22,757 (0%) | 0% | 50.7 | 76,593 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges